ZEALAND PHARMA AS

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: -

Established: 1998-01-01

Employees: 150

Market Cap: $9.1B

Website: https://www.zealandpharma.com/

Clinical Trials

A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Glepaglutide

First Posted Date: 2020-03-24

Last Posted Date: 2021-07-14

Lead Sponsor: Zealand Pharma

Target Recruit Count: 85

Registration Number: NCT04318743

Locations: 🇳🇱
PRA Health Sciences- Location Martini, Groningen, NZ, Netherlands

Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Glepaglutide

First Posted Date: 2019-11-26

Last Posted Date: 2020-11-18

Lead Sponsor: Zealand Pharma

Target Recruit Count: 16

Registration Number: NCT04178447

Locations: 🇵🇱
Specjalistyczne Centrum Medyczne - Prywatny Szpital, Kraków, Poland
🇭🇺
Fázis I-es Klinikai Farmakológiai, Budapest, Hungary
🇭🇺
Szent Imre Egyetemi Oktatókórház, Budapest, Hungary

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Phase 2

Completed

Conditions: Congenital Hyperinsulinism

Interventions: Drug: dasiglucagon
Drug: Placebo

First Posted Date: 2019-11-21

Last Posted Date: 2023-03-15

Lead Sponsor: Zealand Pharma

Target Recruit Count: 12

Registration Number: NCT04172441

Locations: 🇩🇪
University Children's Hospital, Düsseldorf, Germany
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States

and more 3 locations

A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Early Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dual GLP-1/GLP-2 Receptor agonists

First Posted Date: 2019-06-21

Last Posted Date: 2020-12-02

Lead Sponsor: Zealand Pharma

Target Recruit Count: 64

Registration Number: NCT03994549

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Phase 3

Active, not recruiting

Conditions: Congenital Hyperinsulinism

Interventions: Drug: dasiglucagon

First Posted Date: 2019-05-07

Last Posted Date: 2024-04-08

Lead Sponsor: Zealand Pharma

Target Recruit Count: 44

Registration Number: NCT03941236

Locations: 🇩🇪
University Hospital Düsseldorf, Department of Pediatrics, Düsseldorf, Germany
🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States
🇮🇱
Hadassah Medical Center, Jerusalem, Israel

and more 7 locations

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

Phase 3

Recruiting

Conditions: Short Bowel Syndrome

Interventions: Drug: glepaglutide

First Posted Date: 2019-04-05

Last Posted Date: 2023-11-27

Lead Sponsor: Zealand Pharma

Target Recruit Count: 145

Registration Number: NCT03905707

Locations: 🇬🇧
St Mark's Hospital, Harrow, United Kingdom
🇺🇸
Mayo Clinic College of Medicine, Rochester, Minnesota, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

and more 24 locations

A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1
Hypoglycemia

Interventions: Drug: dasiglucagon

First Posted Date: 2019-03-29

Last Posted Date: 2023-02-21

Lead Sponsor: Zealand Pharma

Target Recruit Count: 92

Registration Number: NCT03895697

Locations: 🇨🇦
LMC Diabetes & Manna Research, Toronto, Ontario, Canada

A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Phase 3

Completed

Conditions: Congenital Hyperinsulinism

Interventions: Drug: Dasiglucagon
Other: Standard of Care

First Posted Date: 2018-12-17

Last Posted Date: 2023-12-13

Lead Sponsor: Zealand Pharma

Target Recruit Count: 32

Registration Number: NCT03777176

Locations: 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇬🇧
Alder Hey Children'sHospital NHS Foundation Trust, Liverpool, United Kingdom
🇺🇸
Children's Hospital of Colorado, Aurora, Colorado, United States

and more 7 locations

Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration

Phase 1

Completed

Conditions: Hypoglycemia

Interventions: Drug: Placebo
Drug: Dasiglucagon

First Posted Date: 2018-11-08

Last Posted Date: 2021-03-23

Lead Sponsor: Zealand Pharma

Target Recruit Count: 60

Registration Number: NCT03735225

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

Phase 3

Completed

Conditions: Short Bowel Syndrome

Interventions: Drug: glepaglutide
Drug: Placebo

First Posted Date: 2018-10-01

Last Posted Date: 2024-10-21

Lead Sponsor: Zealand Pharma

Target Recruit Count: 106

Registration Number: NCT03690206

Locations: 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
🇫🇷
Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

and more 26 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy